Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128976) titled 'A clinical study of Zeprumetostat in combination with azacitidine for MDS patients who have no response, relapse, or disease progression after prior first-line therapy' on July 29.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Condition: Myelodysplastic syndrome (MDS)

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-07-31

Target Sample Size: Experimental group:78;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=331812

Published by...